Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Funder: Bladder Cancer Advocacy Network

Funding period
USD 2 K
Funding amount
Abstract
Lysine-specific demethylase 6A (KDM6A) and members of the Switch/Sucrose non-fermentable (SWI/SNF) family are known to counteract the activity of Enhancer of zeste homolog 2 (EZH2), which is often overexpressed and is associated with poor prognosis in muscle-invasive bladder cancer. Here we provide evidence that alterations in chromatin modifying enzymes, including KDM6A and members of the SWI/SNF complex, are frequent in muscle-invasive bladder cancer. We exploit the loss of function mutations in KDM6A and SWI/SNF complex to make bladder cancer cells susceptible to EZH2 based epigenetic therapy that activates an immune response to drive tumor cell differentiation and death. We reveal a novel mechanism of action of EZH2 inhibition, alone and in combination with cisplatin, which induces immune signaling with the largest changes observed in interferon gamma (IFN-?). This upregulation is a result of activated natural killer (NK) signaling as demonstrated by the increase in NK cell-associated genes MIP-1a, ICAM1, ICAM2, and CD86 in xenografts treated with EZH2 inhibitors. Conversely, EZH2 inhibition results in decreased expression of pluripotency markers, ALDH2 and CK5, and increased cell death. Our results reveal a novel sensitivity of muscle-invasive bladder cancer cells with KMD6A and SWI/SNF mutations to EZH2 inhibition alone and in combination with cisplatin. This sensitivity is mediated through increased NK cell-related signaling resulting in tumor cell differentiation and cell death.
Similar projects All >
Sorted by: Start Date
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Modeling bladder cancer pathogenesis and tumor evolution

National Cancer Institute to CORY ABATE-SHEN, DAVID B SOLIT, HIKMAT AL-AHMADIE, MICHAEL M. SHEN

USD 1,765,498
2018 - 2023
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2019
Project list item
Role of B-arrestins in bladder cancer progression and response to chemotherapy

United States Department of Veterans Affairs to BAL L LOKESHWAR

 
2018 - 2022
Project list item
Proteogenomic characterization of muscle invasive bladder cancer to identify mechanisms of resistance and targets for therapy

Bladder Cancer Advocacy Network to Seth P. Lerner, Susan Hilsenbeck, Matthew James Ellis, Keith Syson Chan, Jonathan Michael Levitt, Sung Yun Jung, Anna Malovannaya, Bing Zhang

USD 300,000
2017 - 2019

System

Categories
  • FOR (ANZSRC)

    0601 Biochemistry and Cell Biology

  • RCDC

    Cancer

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science